cefepime
Selected indexed studies
- Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. (Clin Pharmacokinet, 2022) [PMID:35764774]
- Cefepime-induced neurotoxicity: systematic review. (J Antimicrob Chemother, 2022) [PMID:35971666]
- Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination. (Drugs, 2024) [PMID:39214942]
_Worker-drafted node — pending editorial review._
Connections
cefepime is a side effect of
Sources
- Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. (2022) pubmed
- Cefepime-induced neurotoxicity: systematic review. (2022) pubmed
- Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination. (2024) pubmed
- Cefepime/Enmetazobactam: First Approval. (2024) pubmed
- [Cefepime-induced encephalopathy]. (2019) pubmed
- Cefepime Dosing in Neonates: What is the Evidence? (2021) pubmed
- Cefepime. (1995) pubmed
- Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation. (2025) pubmed
- Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor. (2025) pubmed
- In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives. (2025) pubmed